Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin vs standard therapy for relapsed/refractory acute lymphoblastic leukemia
Cancer Mar 16, 2018
Kantarjian HM, et al. - In the phase 3 randomized controlled INO-VATE trial, superior clinical activity of inotuzumab ozogamicin (InO), an anti-CD22 antibody-calicheamicin conjugate, was shown in comparison to standard-of-care (SOC) chemotherapies for relapsed/refractory B-cell acute lymphoblastic leukemia. Herein, patient-reported outcomes (PROs) from that study were evaluated. With the observed superior clinical efficacy and better quality of life (QoL), favorable benefit/risk ratio of InO for the treatment of relapsed/refractory acute lymphoblastic leukemia was supported by the current PRO data.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries